Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)


Rost N. S., Giugliano R. P., Ruff C. T., Murphy S. A., Crompton A. E., Norden A. D., ...Daha Fazla

STROKE, cilt.47, sa.8, ss.2075-2082, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 47 Sayı: 8
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1161/strokeaha.116.013540
  • Dergi Adı: STROKE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2075-2082
  • Anahtar Kelimeler: atrial fibrillation, clinical trial, hemorrhage, risk factors, stroke, PREDICTING STROKE, HEMORRHAGE, METAANALYSIS, RIVAROXABAN, PREVENTION
  • Gazi Üniversitesi Adresli: Evet

Özet

Background and Purpose-Patients with atrial fibrillation and previous ischemic stroke (IS)/transient ischemic attack (TIA) are at high risk of recurrent cerebrovascular events despite anticoagulation. In this prespecified subgroup analysis, we compared warfarin with edoxaban in patients with versus without previous IS/TIA.